Erenumab

Generic Name: Erenumab

Brand Names: Aimovig

Drug Type: Biotech

CAS Number: 1582205-90-0

Unique Ingredient Identifier: I5I8VB78VT

Background: Erenumab (AMG-334) (INN; trade name Aimovig) is a human monoclonal antibody designed specifically to bind and antagonize the calcitonin gene-related peptide receptor (CGRPR) as a means to prevent migraines. Aimovig, as released and marketed by Novartis and Amgen, is in fact a novel therapeutic approach as the first and only FDA approved treatment specifically developed to prevent migraine by blocking the CGRP receptor, which is believed to play a critical role in migraine .

In particular, erenumab-aooe is a human immunoglobulin G2 monoclonal antibody that has high affinity binding to the CGRP receptor . The antibody is produced utlilizing recombinant DNA technology in Chinese hamster ovary cells . It is composed of 2 heavy chains, each containing 456 amino acids, and 2 light chains of the lambda subclass, each containing 216 amino acids, with an approximate molecular weight of 150 kDa .

Indication: Erenumab is indicated for the preventative treatment of migraine in adults .

Associated Conditions: Migraine

Clinical Trials

Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI

Phase 2

Recruiting

Conditions: Posttraumatic Headache
Mild Traumatic Brain Injury

Interventions: Drug: Placebo
Drug: Erenumab 140 Mg/mL Subcutaneous Solution

First Posted Date: 2021-09-17

Last Posted Date: 2024-02-22

Lead Sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine

Target Recruit Count: 404

Registration Number: NCT05049057

Locations: 🇺🇸
Womack Army Medical Center - Fort Liberty, Fort Bragg, North Carolina, United States
🇺🇸
University of Pittsburgh Concussion Research Laboratory, Pittsburgh, Pennsylvania, United States
🇺🇸
William Beaumont Army Medical Center, El Paso, Texas, United States

and more 1 locations

Safety and Efficacy of Erenumab-aooe in Patients With Temporomandibular Disorder

Phase 2

Completed

Conditions: Temporomandibular Disorder

Interventions: Drug: Placebo (EREN-P) s.c. administered every four weeks for a total of five treatments
Drug: Erenumab-aooe (EREN) 140 mg s.c. administered every four weeks for a total of five treatments

First Posted Date: 2021-05-13

Last Posted Date: 2024-08-09

Lead Sponsor: Indiana University

Target Recruit Count: 39

Registration Number: NCT04884763

Locations: 🇺🇸
Indiana University School of Dentistry, Oral Health Research Institute, Indianapolis, Indiana, United States

A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine

Phase 4

Completed

Conditions: Migraine

Interventions: Drug: Erenumab

First Posted Date: 2021-04-01

Last Posted Date: 2023-10-06

Lead Sponsor: Amgen

Target Recruit Count: 240

Registration Number: NCT04825678

Locations: 🇺🇸
Asheville Neurology Specialists PA, Asheville, North Carolina, United States
🇺🇸
New Age Medical Research Corporation, Miami, Florida, United States
🇺🇸
Mountain Neurological Research Center, Basalt, Colorado, United States

and more 39 locations

Registry for Migraine - Structural and Functional MRI Before and After Erenumab Treatment

Phase 4

Recruiting

Conditions: Headache
Migraine

Interventions: Drug: Erenumab

First Posted Date: 2020-12-17

Last Posted Date: 2022-01-10

Lead Sponsor: Danish Headache Center

Target Recruit Count: 250

Registration Number: NCT04674020

Locations: 🇩🇰
Danish Headache Center, Copenhagen, Denmark

CGRP Inhibition, Autonomic Function, and Migraine

Recruiting

Conditions: Episodic Migraine
Chronic Migraine

Interventions: Drug: Erenumab
Drug: Galcanezumab
Drug: Fremanezumab

First Posted Date: 2020-11-13

Last Posted Date: 2024-12-10

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 120

Registration Number: NCT04628429

Locations: 🇦🇹
Medical University of Vienna, Vienna, Austria

Registry for Migraine - Clinical Core

Phase 4

Conditions: Migraine

Interventions: Drug: Erenumab

First Posted Date: 2020-10-27

Last Posted Date: 2020-10-27

Lead Sponsor: Danish Headache Center

Target Recruit Count: 1000

Registration Number: NCT04603976

Locations: 🇩🇰
Danish Headache Center, Glostrup, Denmark

Hypersensitivity to CGRP as a Predictive Biomarker of Migraine Prevention With Erenumab

Phase 4

Recruiting

Conditions: Migraine

Interventions: Drug: Calcitonin Gene-Related Peptide
Drug: Erenumab

First Posted Date: 2020-10-19

Last Posted Date: 2022-10-24

Lead Sponsor: Danish Headache Center

Target Recruit Count: 400

Registration Number: NCT04592952

Locations: 🇩🇰
Danish Headache Center, Copenhagen, Glostrup, Denmark

Efficacy of Erenumab on Functional Impact of Migraine

Phase 4

Completed

Conditions: Migraine

Interventions: Drug: Erenumab-Aooe 140 MG/ML [Aimovig]

First Posted Date: 2020-07-10

Last Posted Date: 2022-10-05

Lead Sponsor: Merle Diamond

Target Recruit Count: 55

Registration Number: NCT04465357

Locations: 🇺🇸
Diamond Headache Clinic, Chicago, Illinois, United States
🇺🇸
StudyMetrix, Saint Peters, Missouri, United States
🇺🇸
Clinvest Research, Springfield, Missouri, United States